Jubilant Therapeutics Announces First Preliminary Clinical Data from Ongoing Phase 1/2 Study of JBI-802 in Patients with Myeloproliferative Neoplasms at SOHO 2026
Presentation highlights data demonstrating that the dual LSD1/HDAC6 inhibitor achieves rapid and sustained dose-responsive reductions in platelet counts in patients with essential thrombocythemia (ET), with consistent activity also observed in polycythemia vera (PV) and other...
Covered in this story
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.